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ErythromycinIn the search for new drugs and drug targets to treat the ﬂatworm disease schistosomiasis, protein
kinases (PKs) have come under particular scrutiny because of their essential roles in developmental
and physiological processes in schistosome parasites. In this context the application of the anti-cancer
Abl tyrosine kinase (TK) inhibitor Imatinib (Gleevec/Glivec; STI-571) to adult Schistosoma mansoni
in vitro has indicated negative effects on diverse physiological processes including survival.
Motivated by these in vitro ﬁndings, we performed in vivo experiments in rodent models of S. mansoni
infection. Unexpectedly, Imatinib had no effect on worm burden or egg-production. We found that the
blood components serum albumin (SA) and alpha-1 acid glycoprotein (AGP or orosomucoid) negated
Imatinib’s deleterious effects on adult S. mansoni and schistosomula (post-infective larvae) in vitro. This
negative effect was partially reversed by erythromycin. AGP synthesis can increase as a consequence of
inﬂammatory processes or infection; in addition upon infection AGP levels are 6–8 times higher in mice
compared to humans. Therefore, mice and probably other rodents are poor infection models for measur-
ing the effects of Imatinib in vivo. Accordingly, we suggest the routine evaluation of the ability of AGP and
SA to block in vitro anti-schistosomal effects of small molecules like Imatinib prior to laborious and
expensive animal experiments.
 2014 Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Three drugs have been available to treat schistosomiasis, metri-Schistosomiasis is caused by a number of schistosome species,
which belong to the class Trematoda within the phylum platyhel-
minthes. According to recent WHO data, about 780 million people
are at risk of infection, and more than 240 million patients require
treatment each year (Ross et al., 2002; Steinmann et al., 2006; King,
2010; World Health Organization, 2013). Besides humans, infec-
tion in farm and wild animals induces similar pathological conse-
quences (De Bont and Vercruysse, 1998; Wang et al., 2006; Wu
et al., 2010). Therefore, schistosomiasis represents not only a med-
ical but also a serious socio-economic problem, which affects both
developing and newly industrializing countries (Huang and
Manderson, 2005; King, 2010; McManus et al., 2010; Chen, 2014).fonate (against Schistosoma haematobium; no longer commercially
available), oxamniquine (active only against Schistosoma mansoni;
restricted availability), and praziquantel (PZQ). The latter is the
only drug effective against all important schistosome species and
consequently, as recommended by the WHO, is the drug of choice
applied in preventive chemotherapy programs worldwide (Harder,
2002; Magnussen, 2003; Fenwick et al., 2006; Mathers et al., 2007;
Stothard et al., 2009; Danso-Appiah et al., 2013). However, PZQ has
notable failings as a drug: (i) it mainly targets the adult worm
whereas the immature forms between 7 and 28 days post-infection
(p.i.) are less susceptible; (ii) complete cure is rarely achieved in
the single 40 mg/kg recommended dose for MDA; (iii) this drug it
is not free of adverse effects (Doenhoff et al., 2008; Caffrey et al.,
2009) and (iv) with the increasingly widespread and regular appli-
cation, there is justiﬁed fear of emerging resistance. Laboratory
experiments have shown that reduced susceptibility against PZQ
is inducible upon selection pressure (Doenhoff et al., 2008; Sabra
and Botros, 2008; Pica-Mattoccia et al., 2009). Clinically relevant
proof of resistance has not been reported yet, however, results of
288 S. Beckmann et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 287–295ﬁeld studies indicate decreased PZQ efﬁcacy (Ismail et al., 1999;
Black et al., 2009; Melman et al., 2009). Due to the availability of
genome data for the three important schistosome species infecting
humans (Berriman et al., 2009; Schistosoma japonicum Genome
Sequencing and Functional Analysis Consortium, 2009; Protasio
et al., 2012; Young et al., 2012), the existence of multidrug-
transporters has been conﬁrmed and initial characterizations
demonstrate that a P-glycoprotein efﬂux pump and multidrug
resistance-associated proteins of S. mansoni are responsive to
PZQ (James et al., 2009; Kasinathan and Greenberg, 2012;
Greenberg, 2013).
Due to the lack of a vaccine and limited drug availability, the
WHO ranks schistosomiasis next to malaria and tuberculosis in
importance as a tropical disease for which novel treatment strate-
gies are urgently needed (Steinmann et al., 2006; Montresor et al.,
2012; World Health Organization, 2013). Many research initiatives
are underway, and new targets have come into focus (Caffrey,
2007; Caffrey and Selzer, 2012; Geary, 2012; Huang et al., 2012;
Prichard et al., 2012). Among these, the TKs that have been exten-
sively studied during the last decade for their pleiotropic functions
in development, growth including mitosis, reproduction, tissue
integrity, and survival (Swierczewski and Davies, 2010; Dissous
and Grevelding, 2011; Buro et al., 2013; de Saram et al., 2013;
Dissous et al., 2013; Andrade et al., 2014). The biological functions
of these TKs and their roles as presumptive candidates for targeting
were elucidated by in vitro-culture of adults and/or larval stages
with small molecule inhibitors and/or RNAi.
Among the TKs studied, the S. mansoni orthologs of the Abelson
murine leukemia (Abl) TKs, SmAbl1 and SmAbl2, have been char-
acterized in particular detail. By in situ hybridization using adults,
transcripts for SmAbl1 and SmAbl2 have been detected in the
gonads, the area surrounding the ootype, and the parenchyma
and/or the gastrodermis indicating their involvement in reproduc-
tion and other physiological processes (Beckmann and Grevelding,
2010). Comparative sequence analyses have shown that these
SmTKs possess the majority of amino acid residues necessary for
human Abl-kinase to bind to Imatinib (Nagar et al., 2002;
Beckmann and Grevelding, 2010). Imatinib is a small-molecule
inhibitor marketed as Glivec (Gleevec/STI-571), it acts as a compet-
itive antagonist of the adenosine triphosphate (ATP) binding site of
Abl-TKs, and is used to treat chronic myelogenous leukemia and
other human cancers (Manley et al., 2002; Larson et al., 2008). Bio-
chemical studies have conﬁrmed that both schistosome Abl-TKs
are targets for Imatinib (Beckmann et al., 2011; Buro et al.,
2014). Studies with adult schistosomes in vitro demonstrated dose-
and time-dependent effects of Imatinib, including body swellings,
defects in locomotion, reduced pairing stability and viability.
Microscopic analyses revealed degenerative changes within the
gonads such as disordered apoptotic oogonia and smaller testes
with defective sperm differentiation. The most remarkable effect,
however, was the degradation of the gastrodermis that caused
the death of the parasites (Beckmann and Grevelding, 2010).
To further analyze the potential of Imatinib as an anti-schisto-
somal therapy, we employed mouse and hamster infection models
as well as in vitro studies to investigate the effect of Imatinib in vivo
and in vitrowith a special focus on speciﬁc host-blood components.2. Material and methods
2.1. Parasite stocks
Adult and larval schistosome stages originated from a Liberian
(Grevelding, 1995) and a Puerto Rican (Abdulla et al., 2009) isolate
of Schistosoma mansoni, respectively. Both were maintained in
snails (Biomphalaria glabrata) and Syrian hamsters (Mesocricetusauratus). Cercariae were obtained from snails after 30 days of infec-
tion. Adult parasites were obtained by hepato-portal perfusion at
42–49 days p.i. as described before (Grevelding, 1995; Abdulla
et al., 2009). Experiments were approved by the regional council
Giessen, Germany (V54-19 c 20/15 c GI 18/10 and V54-19 c 20/
15 (1) GI 18/10 – Nr.75/2009). All animal procedures performed
at the UCSF, USA, were done in accordance with protocols
approved by the UCSF Institutional Animal Care and Use Commit-
tee (IACUC) as required by the Federal Animal Welfare Act and the
National Institutes of Health Public Health Service Policy on
Humane Care and Use of Laboratory Animals (http://grants.
nih.gov/grants/olaw/references/phspol.htm).2.2. Infection and treatment of rodents
For these experiments 12 mice (NMRI) and 12 hamsters (Mesoc-
rietus auratus) were used in Giessen (Germany), and 6 hamsters
(Mesocrietus auratus) at the UCSF (USA). In Giessen, infections with
schistosomes were performed by the paddling method as
described before using 2000 cercariae per hamster and 800 per
mouse (Grevelding, 1995). At the UCSF, 4–6 week old, female ham-
sters were infected sub-cutaneously with 800 cercariae of a Puerto
Rican isolate of S. mansoni (Abdulla et al., 2009).
Previously obtained data indicated killing of adult parasites
within 1-2 days using 100 lM, or within 4–7 days using 1–10 lM
in vitro (Beckmann and Grevelding, 2010; Dissous and
Grevelding, 2011). Experiments in the mouse model have shown
an elimination half-life of 1.3 h for Imatinib in mice and tissue/
plasma concentration ratios of Imatinib of about 3.76 ± 1.09, and
12.0 ± 6.3 lg/ml after applications of 25 mg/kg or 50 mg/kg (Teoh
et al., 2010). For liver, tissue/plasma concentration ratios between
19.2 ± 13.3 lg/g, and 61.4 ± 40.1 lg/g were determined after mul-
tiple dosages of 25 mg/kg or 50 mg/kg, respectively (Teoh et al.,
2010). With respect to these data and pharmacokinetic consider-
ations concerning the application of a drug for humans in rodents
(Fabbro et al., 2002; Kretz et al., 2004; Löscher et al., 2006) differ-
ent dosages of 20–100 mg/kg body weight were applied. From days
40 p.i. or 34 p.i. on, Imatinib (dissolved in 0.9% NaCl) was given at a
daily basis by gavage over 4-days or 10-days periods, respectively,
which was conducted by a veterinarian. The constitution of the
animals was checked daily. One day after the ﬁnal treatment, the
animals were euthanized and the parasites recovered by perfusion.2.3. In vitro culture of adult schistosomes
After perfusion, adult schistosomes were washed three times
with M199 medium before being cultured in the same medium
(Gibco; including glucose, sodium bicarbonate, 4-(2-hydroxy-
ethyl)-1-piperazineethane sulfonic acid) supplemented with an
antibiotic/antimycotic mixture (1%, Sigma) and new born calf
serum (NCS) (10%, Sigma Aldrich) at 37C and 5% CO2 as described
before (Beckmann and Grevelding, 2010; Beckmann et al., 2012).
For each experiment, 5–10 S. mansoni couples were kept per well
in 6-well or 12-well plates with 2–3 ml culture medium per well.
The medium was changed every 24 h. All following experiments
were done in duplicate. To investigate the inﬂuence of serum albu-
min (SA), adult S. mansoni couples were maintained in culture
medium, which contained 1.93 g/L SA due to the supplemented
NCS. Because the in vivo concentration of albumin in blood of mice
or humans is much higher with 44 g/L (mice) or 35–55 g/L
(human), the culture medium was supplemented with BSA or
HSA in a concentration of 43 g/L to achieve a ﬁnal albumin concen-
tration of 45 g/L, reﬂecting the in vivo situation. S. mansoni couples
were treated in these different media (without additional SA, with
BSA, or with HSA) with Imatinib (0, 10, or 50 lM) for 6 days.
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and survival were investigated.
Correspondingly, human alpha acidic glycoprotein (AGP; Sigma
Aldrich) was added to the culture medium in a concentration of
0.8 g/L. Erythromycin was used in the culture medium in a ﬁnal
concentration of 20 or 40 lM, dissolved from a standard solution
(Sigma Aldrich). S. mansoni couples were treated in varying culture
media with different concentrations (10–20 lM) of Imatinib (Enzo
Life Sciences; dissolved in water) up to 4 days. Pairing status, egg
production, morphology and vitality of treated or control parasites
were documented by bright-ﬁeld microscopy on a daily basis.
2.4. In vitro culture of larval schistosomes
Cercariae were harvested and mechanically transformed into
schistosomula as described (Abdulla et al., 2009). Schistosomula
were cultured in 96-well plates (200 parasites/well) for four days
at 37C with 5% CO2 in Basch medium 169 (Basch, 1981) supple-
mented with 5% FBS (fetal bovine serum). Morphology and vitality
of treated or control schistosomula were measured by bright-ﬁeld
microscopy on a daily basis as described (Rojo-Arreola et al., 2014).
Measurements were performed in duplicate.3. Results
3.1. Schistosomes are not affected by Imatinib treatment in rodents
Motivated by the promising results obtained in vitro, animal
experiments were performed to investigate whether Imatinib
affects the physiology and survival of adult parasites also in vivo.
Based on previous data on the effect of Imatinib on adult S. mansoni
in vitro and plasma- as well as tissue-concentrations of this drug in
treated mice (Teoh et al., 2010) we expected that the application of
20-100 mg/kg over 4-10 days starting 34 or 40 days p.i. are sufﬁ-
cient to negatively affect schistosome reproduction and survival
along the application period. Following perfusion and inspection
of parasites perfused from mice treated over 4 or 10 days with
up to 100 mg/kg, we surprisingly noted no differences of worm
number, pairing stability, egg production or survival parameters
(sucking capability to the Petri dish, mobility, gut peristalsis) com-
pared to the control (data not shown).
3.2. SA decreases the detrimental effects of Imatinib on adult
S. mansoni in vitro
Binding of Imatinib to SA has been reported to negatively inﬂu-
ence the activity of Imatinib in vivo (Fitos et al., 2006). However, for
schistosomes, albumin is also discussed as a good drug carrier for
chemotherapeutic substances like anthelmintics because it
appears to be an important source of energy supply for adult par-
asites (Bennett and Caulﬁeld, 1991; Delcroix et al., 2006; Holtfreter
et al., 2010). Therefore, it was also conceivable that albumin could
positively inﬂuence Imatinib efﬁcacy on schistosomes.
Without additional SA in the culture medium, the couples had
separated by 24 and 72 h in the presence of 50 and 10 lM Imatinib,
respectively (Fig. 1A). In each case, the couples were no longer
attached to the bottom of the culture plates, were slower, and less
vital. Also, bulges recorded previously as one of the consequences
of Imatinib treatment (Beckmann and Grevelding, 2010) were dis-
tributed along the body. After 156 h, all of the parasites had died. In
comparison, medium enriched with BSA or HSA (45 g/L ﬁnal con-
centration) delayed these effects to different degrees. With BSA
in the culture medium, couples exposed to 50 lM Imatinib did
not become separated before 96 h; in the presence of 10 lM Imati-
nib couples did not separate at all (Fig. 1B). Correspondingly, with50 lM Imatinib a reduced vitality and small bulges were ﬁrst
observed after 84 h, and after 156 h, these parasites were dead.
Using 10 lM Imatinib and BSA, no inﬂuence on physiology or
moving capacity was observed. With HSA in the culture medium,
the couples separated completely after 72 h (with 50 lM Imatinib)
or 156 h (with 10 lM Imatinib) (Fig. 1C). With 50 lM Imatinib, the
schistosomes were no longer attached to the culture dish within
48 h under these conditions, showed reduced moving, vitality
and bulges after 48–72 h, and they died after 156 h. Using 10 lM
Imatinib, however, no killing was observed although the parasites
displayed decreased movement and vitality after 156 h.
These in vitro results indicate that SA decreased the efﬁcacy of
Imatinib on adult S. mansoni in vitro. Furthermore, we noted that
compared to HSA, BSA exerted a stronger inhibition of Imatinib.
3.3. AGP decreases the detrimental effects of Imatinib on adult S.
mansoni in vitro
Like SA, AGP has also been reported to bind to Imatinib, thus
negatively inﬂuencing its therapeutic activity in cancer patients
(Kremer et al., 1988; Gambacorti-Passerini et al., 2000; Fitos
et al., 2006, 2012; Hegde et al., 2012). To investigate the effect of
AGP in our system, adult S. mansoni couples were maintained in
culture medium, which was supplemented with human AGP at a
ﬁnal concentration of 0.8 g/L, similar to that found in human
plasma (0.5–1.4 g/L) (Schultz and Arnold, 1990; Gambacorti-
Passerini et al., 2000). In addition, the medium contained 1.93 g/L
albumin due to the supplemented NCS.
Control couples (no Imatinib treatment) maintained in culture
medium with and without AGP showed no differences in morphol-
ogy, behavior or vitality (Supplementary data 1, 2). However,
within 48–72 h clear differences were observed between schisto-
somes treated with Imatinib in the presence or absence of AGP.
Thus, in the presence of 20 lM Imatinib but without AGP, couples
had separated and detached from the culture dish, were morpho-
logically abnormal (bulges and swellings; Fig. 2B), and died after
96 h. In contrast, in the presence of AGP, schistosomes remained
paired, adhered to the petri dish (Fig. 2D), and were apparently
similar to control couples (Fig. 2A, C). Using 10 lM Imatinib,
similar observations were made within 72–96 h (Supplementary
data 3, 4).
Previous studies have demonstrated that antibiotics such as
erythromycin compete with Imatinib for binding of AGP
(Gambacorti-Passerini et al., 2000, 2002; Azuma et al., 2007). As
erythromycin has the potential to indirectly increase the concen-
tration of free Imatinib, we hypothesized that this antibiotic may
rescue the schistosomicidal effect of Imatinib in the presence of
AGP. When erythromycin was added to culture medium at concen-
trations of 20 or 40 lM, the inhibitory effect of AGP on the Imatinib
(20 lM) response was abolished: couples separated, detached from
the culture dish, showed reduced movement and morphological
perturbations (bulges and swellings along the body; Fig. 2F). These
parasites had similar phenotypes as those treated in mediumwith-
out AGP, and they also died within 96 h. Corresponding observa-
tions were made for the couples treated with 10 lM Imatinib
(Supplementary data 5, 6). Erythromycin alone also negatively
affected the vitality of the schistosome couples, but only after
treatment periods exceeding ﬁve days (data not shown). In addi-
tion to direct effects on schistosomes, decreased egg production
was measured. Whereas couples in medium (with and without
AGP; 0, 20, or 40 lM erythromycin; 0 lM Imatinib) laid normal
eggs (Fig. 3A, B), the couples treated with Imatinib in medium
without AGP (0, 20, or 40 lM erythromycin) laid less eggs. Instead
of eggs, a lot of vitellocytes and oocytes were detected in the cul-
ture medium (Fig. 3C, E). When the couples were treated with
Imatinib (20 lM) in medium with AGP, normal eggs were laid
Fig. 1. Inﬂuence of serum albumin on pairing stability of Imatinib-treated S. mansoni couples. S. mansoni couples were treated for up to 156 h in vitro with 0/10/50 lM
Imatinib in medium with and without bovine or human serum albumin. The effect of the treatment was monitored over time (0–156 h; x-axis) analysing pairing stability
(given in % values on the y-axis). (A) treatment in normal M199 medium, (B) treatment in medium with BSA (45 g/L), C: treatment in medium with HSA (45 g/L).
Unexpectedly, all schistosomes treated with 10 lM Imatinib and HSA (C) had separated after 156 h of treatment, which in this speciﬁc case is unlikely to be a consequence of
inhibitor treatment alone. Light grey: 0 lM Imatinib, grey: 10 lM Imatinib, dark grey: 50 lM Imatinib.
290 S. Beckmann et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 287–295again, and no free vitellocytes and oocytes were found in the med-
ium (Fig. 3D). However, when erythromycin (20 lM or 40 lM) was
added additionally, egg production decreased, and again vitello-
cytes and oocytes were deposited into the medium (Fig. 3F).
These results demonstrate the negative inﬂuence of AGP on the
schistosomicidal effect of Imatinib, an inﬂuence that can be
reversed by erythromycin.
3.4. SA and AGP combined exert the strongest effect on the potency of
Imatinib
In a combined treatment approach, S. mansoni couples were
treated with 10 lM Imatinib in medium containing HSA up to a
concentration of 45 g/L, 0.8 mg/ml AGP and, additionally, erythro-
mycin at a ﬁnal concentration of 20 lM. In the ﬁrst seven days, no
changes to control couples without Imatinib in the medium were
observed. After 8 days, a slightly reduced vitality of the Imatinib-
treated schistosomes was observed as well as a higher number of
separated couples (50%) as well as schistosomes which were no
longer attached to the petri dish (70%). After 14 days, the Imati-
nib-treated parasites still showed reduced vitality, but did not
die (data not shown). Thus, erythromycin could not completelyreinstate the anti-schistosomal effect of Imatinib in the presence
of both HSA and AGP.
3.5. Imatinib kills schistosomula in vitro but efﬁcacy is decreased by
BSA and AGP
In vitro experiments were performed to test whether Imatinib
kills schistosomula and whether SA and/or AGP decrease the inhib-
itor’s efﬁcacy. When treated with Imatinib alone (10 lM and
20 lM; 24 h to 96 h), schistosomula degenerated (becoming
rounded and dark) and eventually died. These effects occurred in
a dose- and time-dependent manner (Fig. 4A, B).
In contrast, schistosomula treated with different concentrations
of Imatinib in medium supplemented with BSA (45 g/L) were phe-
notypically similar to DMSO controls. Also the addition of AGP
(0.8 g/L) to the medium inﬂuenced the effect of Imatinib. Although
not completely reversed, the Imatinib effect was delayed by AGP.
Consequently, the concurrent addition of both BSA and AGP to
the medium blocked the Imatinib effect as well, but the numbers
of degenerate parasites obtained by combining these blood
components did not signiﬁcantly differ from those of the BSA-only
treatment group. The presence of erythromycin as a single
Fig. 2. Inﬂuence of alpha-1 acid glycoprotein against erythromycin addition on pairing-stability and physical integrity of Imatinib-treated S. mansoni couples. S. mansoni
couples were treated for 3 days in vitro with 20 lM Imatinib in medium with and without 0.8 g/L AGP as well as with or without 20 lM erythromycin. (A) 0 lM Imatinib,
M199; (B): 20 lM Imatinib, M199; (C): 0 lM Imatinib, M199 + AGP; (D): 20 lM Imatinib, M199 + AGP; (E) 0 lM Imatinib, 20 lM erythromycin, M199 + AGP; (F) 20 lM
Imatinib, 20 lM erythromycin, M199 + AGP. Scale bars: 1 mm; ⁄bulges and #gut alterations indicating the deleterious effect of Imatinib.
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on vitality of schistosomula (data not shown). Erythromycin
(20 lM or 40 lM) partially reversed the negative inﬂuence of
AGP on Imatinib beginning at 48 h after treatment. However, when
BSA and AGP were added simultaneously with the inhibitor (up to
20 lM), erythromycin was unable to reverse the negative effect of
Imatinib (data not shown).4. Discussion
4.1. SA and AGP impede the effect of Imatinib on schistosomes
Recently, the search for alternative treatments for schistosomi-
asis and other infectious diseases caused by parasites in humans
and animals has gained momentum. Many initiatives have identi-
ﬁed putative candidate molecules, often accompanied by the char-
acterization of genes and/or proteins and their importance for
parasite biology. Whether or not the putative target(s) is known,
the literature is full of reports on the in vitro identiﬁcation of prom-
ising anti-schistosomal compounds. Experiments involving animal
(rodent) models of infection are then required to conﬁrm the
effects observed in vitro. However, very often in vivo studies fail
in this regard (Keiser, 2010; Rodriguez et al., 2010; Murthy et al.,2011; Da’dara et al., 2013; Katz et al., 2013; Soeiro et al., 2013; this
study). Likewise, our studies with Imatinib suggest that there is a
remarkable discrepancy between the in vivo and the vitro results
that registered dramatic effects on adults (Beckmann and
Grevelding, 2010; Beckmann et al., 2012) and schistosomula (this
study), and the lack of schistosomicidal activity in vivo (Katz
et al., 2013; this study). This unexpected result corresponded to
(i) similar treatment experiments with schistosome-infected
hamsters, in which compared to the mouse model even higher
plasma concentrations of Imatinib were determined (about
42 lM after 30 min and about 12 lM after 6 h following a 60 mg/
kg dosage; data not shown) but also (ii) to recent data obtained
in a parallel study where Imatinib treatment of adult worms
showed similar in vitro effects but no obvious in vivo effects in mice
treated with up to even 1000 mg/kg (Katz et al., 2013).
Although SmAbl1 and SmAbl2 were identiﬁed as targets of
Imatinib (Beckmann and Grevelding, 2010; Beckmann et al.,
2011), and although this small-molecule inhibitor had been suc-
cessfully applied in cancer studies using the mouse (Manley
et al., 2002; Waller, 2010), Imatinib has no effect on the schisto-
some parasite in rodents. It is known that serum levels of Imatinib
in mice after administration of up to 50 mg/kg range between 3
and 12 lg/ml (6–24 lM; Teoh et al., 2010), which is in the range
of those concentrations that affect vitality of adult schistosome
Fig. 3. Inﬂuence of alpha-1 acid glycoprotein against erythromycin on egg production of Imatinib-treated S. mansoni couples. Overview of egg production of S. mansoni
couples, which were treated with 20 lM Imatinib in medium with and without 0.8 g/L AGP as well as with or without 20 lM erythromycin in vitro for 3 days. (A)
0 lM Imatinib, 0 lM Imatinib/20 lM erythromycin, M199; (B) 0 lM Imatinib, 20 lM erythromycin, M199 + AGP; (C) 20 lM Imatinib, 0 lM erythromycin, M199; (D) 20 lM
Imatinib, 0 lM erythromycin, M199 + AGP; (E) 20 lM Imatinib, 20 lM erythromycin, M199; (F) 20 lM Imatinib, 20 lM erythromycin, M199 + AGP. V = vitellocytes,
O = oocytes; scale bars: 50 lM.
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Also, in human patients Imatinib was found to be rapidly absorbed
leading to mean maximal concentration of 2.3 lg/ml (4.6 lM)
when 400 mg were applied once a day with a half-life of the drug
in the circulation ranging from 13-16 h, and the drug level
increased by a factor of 2–3 at steady state with once-daily dosing
(Druker et al., 2001; Awidi et al., 2010; Ishikawa et al., 2010).
To answer the question why the in vivo studies using Imatinib in
the mouse and hamster models failed, we focused on SA and AGP as
they are known to bind to drugs negatively inﬂuencing their action
(Piafsky, 1980; Kremer et al., 1988; Svensson et al., 1986). This
includes Imatinib, which was reported to be bound by both of these
major blood components (Gambacorti-Passerini et al., 2000; Fitos
et al., 2006, 2012; Hegde et al., 2012). Whereas no evidence was
reported for a negative inﬂuence of HSA for Imatinib activity
(Hegde et al., 2012), there are controversial opinions about the
consequences of its interaction with AGP. Some studies describe a
negative inﬂuence (Gambacorti-Passerini et al., 2000, 2003;
Azuma et al., 2007). Yet in another report little impact of AGP on
Imatinib activity was found (Ishikawa et al., 2010). The results
obtained in our study clearly indicate that both SA and AGP
decrease Imatinib’s efﬁcacy on schistosomula, adult schistosomes,
and egg production. Although the effect was slow, the addition ofeither BSA or HSA led eventually to the death of adults incubated
with Imatinib. This indicates that SA as such does not decisively
inﬂuence Imatinib´s action on adults in a negative way. Further-
more, we observed a difference in the anti-Imatinib activity of
HSA and BSA. The latter seemed to disable Imatinibmore efﬁciently,
which may be due to structural differences.
Compared to SA, AGP exerted a stronger negative effect on the
activity of Imatinib against adult S. mansoni. Whereas worm
couples died within 96 h following exposure to 10–20 lM
Imatinib, couples treated the same way but in the presence of
AGP survived this time period and seemed unaffected. The
combination of BSA and AGP showed the strongest negative
inﬂuence on Imatinib´s efﬁcacy in adults.
These in vitro ﬁndings for adults were similar to our observa-
tions made with Imatinib-treated schistosomula, which reacted
less susceptible when SA and AGP were present in the medium.
In schistosomula, however, SA revealed a more pronounced effect
on Imatinib action than AGP. We cannot explain this observation
at this stage of the analysis. In a previous study with schistosomes,
SA uptake was shown for schistosomula and adults suggesting that
albumin is a source of energy (Bennett and Caulﬁeld, 1991;
Delcroix et al., 2006; Holtfreter et al., 2010). With respect to the
fact that SA may also serve as carrier for drugs (Tesseromatis and
Fig. 4. In vitro effects of Imatinib on schistosomula treated additionally with BSA, AGP, and erythromycin. Newly transformed schistosomula were incubated with different
concentrations of Imatinib (0, 10, 20 lM) and compared to the effects caused by the addition of BSA (45 g/L), AGP (0.8 g/L), and erythromycin (20 and 40 lM). (A) Graphical
representation of the percentage of degenerate schistosomes (y-axis) in different conditions (x-axis). Normal versus ‘‘degenerate’’ schistosomes were counted manually in
different conditions during 96 h. Error bars represent standard deviation of two independent experiments performed in duplicate. (B) Images display representative pictures
of schistosomula treated with Imatinib (y-axis), with and without BSA, AGP and/or erythromycin during 96 h (x-axis).
S. Beckmann et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 287–295 293Alevizou, 2008), it was concluded that SA may be a carrier for
anthelmintics in drug-targeting models. With respect to our ﬁnd-
ings, a potential carrier function of SA for Imatinib did not posi-
tively inﬂuence the drug´s potential to kill schistosomes. Thus it
appears questionable, whether the SA-assisted drug transport
and uptake by schistosomes or other SA-importing parasites may
enhance drug efﬁcacy. This may depend on the class of drugs trans-
ported and has to be tested for each candidate compound.
As an additional test to conﬁrm AGP’s negative inﬂuence on
Imatinib’s efﬁcacy, we performed competition experiments adding
erythromycin to this system. This antibiotic binds to AGP, and it
has the potential to enhance the efﬁcacy of other drugs, including
Imatinib, if applied in parallel (Gambacorti-Passerini et al., 2002;
Azuma et al., 2007; Hegde et al., 2012). When we added erythro-
mycin to adult parasites or schistosomula in the presence of both
Imatinib and AGP we observed a partial reinstatement of Imatinib´s
anti-parasite activities. On the one hand, this result is another
indication of the negative role of AGP in inﬂuencing Imatinib´s
efﬁcacy. On the other, this ﬁnding may open novel perspectives
on how to follow test applications of small-inhibitor drugs if they
reveal AGP-binding capacity. Combinations of erythromycin and
the drug of choice may positively inﬂuence drug´s efﬁcacy.
However, against both adults and schistosomula, in the used
concentrations erythromycin was unable to reverse the combined
effects of SA and AGP on Imatinib´s efﬁcacy.
5. Conclusions
The results of this study allow the following conclusions:
1. AGP and SA inﬂuence the efﬁcacy of Imatinib, which explains
the discrepancy of the in vitro and in vivo results obtained in
this and earlier studies. Our ﬁndings may set a precedent fortesting drugs in other in vitro parasite systems, and future
in vitro studies should consider including BSA/HSA and AGP
competition-assays.
2. As models, the mouse and perhaps other rodents such as ham-
sters and rats are not suitable for compound tests if those com-
pounds have been shown to bind AGP. Besides its role as
transporter for different kinds of molecules, AGP fulﬁlls an addi-
tional role as an acute phase protein during infections
(Hochepied et al., 2003). Indeed, AGP levels in mice can increase
30–40 times during infection (Gambacorti-Passerini et al., 2000,
2003). This compares to only a 5-times increase in humans dur-
ing infection (Kremer et al., 1988; Schultz and Arnold, 1990;
Gambacorti-Passerini et al., 2003). Accordingly, rodents are
not ideal models for ‘‘AGP-sensitive’’ compounds. Alternative
models, such as rhesus monkeys (McMullen et al., 1967;
Cheever and Powers, 1969), which may be much closer to
humans with respect to AGP-levels upon infection, or even pigs
may be better suited. Indeed, the pig was recently described as
the ﬁrst organism, in which AGP levels are negatively correlated
with the acute phase of infection (Heegaard et al., 2013).Acknowledgements
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